The underlying molecular mechanisms need to be analyzed in further detail to understand the exact relationships between MEK inhibition and amelioration of IR, which will lead to deeper insights into alternative therapeutic strategies for treating IR or T2D. The gene discussed is MAP2K7; the disease is type 2 diabetes mellitus.